Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using 18F-FDG PET/CT for Monitoring Treatment Response
Publication: Cancer Biotherapy and Radiopharmaceuticals
Volume 31, Issue Number 3
Abstract
Purpose: In vivo efficacy of two herbal extracts of Gloriosa superba L. (Colchicaceae) was investigated in a murine pancreatic tumor model by tumor volume measurements and Positron Emission Tomography (PET) imaging using 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG).
Materials and Methods: A crude extract of G. superba (GS) seeds rich in colchicine and a colchicine-poor extract (GS2B) containing mostly colchicoside as a putative prodrug were prepared. PANC02-bearing C57BL/6 mice were treated with either placebo, gemcitabine, or one of the extracts (three different doses) for 10 days. Tumor volume measurements were performed daily during treatment and additionally 18F-FDG Positron emission tomography/computed tomography was acquired at baseline and after 7 days of treatment. Ki-67 and cleaved caspase-3 immunostaining was performed on the resected tumors.
Results: After 7 days of treatment, a dose-dependent tumor growth inhibition of both extracts was observed with the highest in vivo response at the highest dose of GS and GS2B and gemcitabine. A positive significant correlation was found between Ki-67 scores and relative tumor volumes (RTV), and a negative significant correlation between caspase-3 staining scores and RTV. A decrease in 18F-FDG uptake was clearly observed in all treatment groups.
Conclusions: The therapeutic efficacy of the two different herbal extracts was demonstrated in an in vivo pancreatic tumor model. 18F-FDG PET was able to detect an early response as overall lower 18F-FDG uptake was measured in the treated groups.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year. Ann Oncol 2013;24:792.
2.
Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol 2014;5:280.
3.
Maroyi A, Van der Maesen LJG. Gloriosa superba L. (family Colchicaceae): Remedy or poison? J Med Plants Res 2011;5:6112.
4.
Jana S, Shekhawat GS. Critical review on medicinally potent plants species: Gloriosa superba. Fitoterapia 2011;82:293.
5.
Yue QX, Liu XA, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med 2010;76:1037.
6.
Hastie SB. Interactions of colchicine with tubulin. Pharmacol Therapeut 1991;51:377.
7.
Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65.
8.
Canonica L, Danieli B, Manitto P, et al. New Alkaloids from Gloriosa Superba L. Chim Ind 1967;49:1304.
9.
Chaudhuri PK, Thakur RS. 1,2-Didemethylcolchicine: A new alkaloid from Gloriosa Superba. J Nat Prod 1993;56:1174.
10.
Suri OP, Gupta BD, Suri KA, et al. A new glycoside, 3-O-demethylcolchicine-3-O-alpha-D-glucopyranoside, from Gloriosa superba seeds. Nat Prod Lett 2001;5:217.
11.
Poutaraud A, Girardin P. Agronomical and chemical variability of Colchicum autumnale. Can J Plant Sci 2006;86:547.
12.
Chitra R, Rajamani K. A rapid high-performance liquid chromatographic method for quantitative analysis of anti-cancerous active components in Gloriosa superba tubers. Pharmacogn J 2009;1:138.
13.
Ade R, Rai MK. Review: Current advances in Gloriosa superba L. Biodiversitas 2009;10:211.
14.
Cocco G, Chu D, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Internal Med 2010;21:503.
15.
Friend DR, Chang GW. Drug glycosides: Potential prodrugs for colon-specific drug delivery. J Med Chem 1985;28:51.
16.
Kayed H, Meyer P, He Y, et al. Evaluation of the metabolic response to cyclopamine therapy in pancreatic cancer xenografts using a clinical PET-CT system. Transl Oncol 2012;5:335.
17.
Serrano OK, Chaudry MA, Leach SD. The role of PET scanning in pancreatic cancer. Adv Surg 2010;44:313.
18.
Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670.
19.
Capistrano I R. Phytochemical, Analytical and Preclinical Investigations on Plant Extracts as Potential Antitumoural Therapy. PhD Thesis, University of Antwerp, Belgium. chapter 2015;4.4:128.
20.
Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997;208:151.
21.
Plowman J, Camalier R, Alley M, et al. US-NCI testing procedures. In: Feibig HH, Burger AM (eds.), Relevance of Tumor Models for Anticancer Drug Development. Basel: Karger, 1999;121.
22.
Yamazaki S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: A case study of anticancer drug, crizotinib. Aaps J 2013;15:354.
23.
Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008;68:8322.
24.
Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-KB–regulated gene products. Cancer Res 2007;67:3853.
25.
Shah N, Zhai G, Knowles JA, et al. 18F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol 2012;14:237.
26.
Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972.
27.
Brepoels L, Stroobants S, Vandenberghe P, et al. Effect of corticosteroids on 18F-FDG Uptake in tumor lesions after chemotherapy. J Nucl Med 2007;48:390.
28.
Spaepen K, Stroobants S, Dupont P, et al. [18F]FDG PET monitoring of tumor response to chemotherapy: Does [18F]FDG uptake correlate with the viable tumor cell fraction? EJNMMI 2003;30:682.
29.
Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F18]FLT and positron emission tomography. Nat Med 1998;4:1334.
30.
Soloviev D, Lewis D, Honess D, et al. [(18)F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 2012;48:416.
31.
Johnbeck CB, Jensen MM, Nielsen CH, et al. 18F-FDG and 18F-FLT PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: Studies in human tumor xenografts in mice. PLos One 2014;9:e91387.
Information & Authors
Information
Published In
Cancer Biotherapy and Radiopharmaceuticals
Volume 31 • Issue Number 3 • April 2016
Pages: 99 - 109
PubMed: 27093343
Copyright
Copyright 2016, Mary Ann Liebert, Inc.
History
Published online: 19 April 2016
Published in print: April 2016
Topics
Authors
Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.